Anderson Mark Monroe
Transaction: 10/22/2018
OTHER
Change
0
Price
Not reported
Filing
11/01/2018
Type
OTHER
Evotec SE
EVO • Drug Manufacturers - Specialty & Generic
$1.86
▼ -0.04 (-2.11%)
Current price
EarningsLatest report: Mar 31, 2026
BALANCED PROFILENeutralConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$660.53M
Growth
—
Cash Flow
2/5
Trend
Volatile
Evidence
Manageable debt level · 0.55Healthy liquidity · 2.07Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 6, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$1.86
Change-2.11%
Shares Out355.12M
Market Cap$660.53M
52W Range2.31 - 4.42
Beta1.30
P/E-1.03
P/S3.20
P/B0.73
P/FCF-79.56
EV/Sales4.82
EV/EBITDA-7.88
Price$1.86
Change-2.11%
Shares Out355.12M
Market Cap$660.53M
52W Range2.31 - 4.42
Beta1.30
P/E-1.03
P/S3.20
P/B0.73
P/FCF-79.56
EV/Sales4.82
EV/EBITDA-7.88
EV/FCF-119.70
Earnings Yield-24.29%
FCF Yield-1.26%
Dividend Yield0.00%
Gross Margin8.27%
Oper. Margin-17.87%
Profit Margin-13.13%
Debt/Eq0.55
Current Ratio2.07
Quick Ratio1.99
Target$3.00
Target Upside61.29%
Target Median$3.00
Target Range2.00 - 4.00
Volume27.94K
Avg Volume73.65K
EPS Surprise-0.33
Investment DNA
How strong this company looks for long-term investors
57
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
73/100
Growth Potential
Revenue and expansion
75/100
Price Attractiveness
Cheap or expensive today
93/100
Why this score▼
Manageable debt level · 0.55Healthy liquidity · 2.07Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 7 analyst votes · 2026-09-05
79/100
Bullish
Bullish
4
Hold
3
Bearish
0
Price Target
2026-08-14
Low
$2.00
Mean
$3.00
Median
$3.00
High
$4.00
Insider Transactions
Recent executive and insider activity
Anderson Mark Monroe
Transaction: 10/22/2018
BUY
Change
+100,000
Price
$2.50
Filing
11/01/2018
Type
BUY
Smith Scott Clifford
Transaction: 08/13/2018
OTHER
Change
0
Price
Not reported
Filing
10/29/2018
Type
OTHER
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Anderson Mark Monroe | OTHER | 0 | Not reported | 10/22/2018 | 11/01/2018 |
| Anderson Mark Monroe | BUY | +100,000 | $2.50 | 10/22/2018 | 11/01/2018 |
| Smith Scott Clifford | OTHER | 0 | Not reported | 08/13/2018 | 10/29/2018 |
| Smith Scott Clifford | BUY | +100,000 | $2.50 | 08/13/2018 | 10/29/2018 |
| LAFFER ARTHUR B | OTHER | 0 | Not reported | 08/13/2018 | 10/12/2018 |
| LAFFER ARTHUR B | BUY | +100,000 | $2.50 | 08/13/2018 | 10/12/2018 |
| QUINTON KEITH | OTHER | 0 | Not reported | 10/01/2018 | 10/03/2018 |
| Smith Marcus L. | OTHER | 0 | Not reported | 10/01/2018 | 10/02/2018 |
| Zientek Michael | BUY | +200,000 | $2.50 | 08/13/2018 | 10/02/2018 |
| Zientek Michael | SELL | 0 | Not reported | 07/25/2018 | 10/02/2018 |
| BANK OF AMERICA CORP /DE/ | SELL | -134 | Not reported | 03/26/2018 | 03/28/2018 |
| BRANDON CRAIG R | OTHER | 0 | Not reported | 06/22/2016 | 06/24/2016 |
| HYLTON LAURIE G | OTHER | 0 | Not reported | 06/01/2016 | 06/01/2016 |
| UBS Group AG | SELL | -531 | Not reported | 02/26/2016 | 03/01/2016 |
| UBS Group AG | OPTION | 0 | Not reported | 11/28/2014 | 12/02/2014 |
| Esty Benjamin | OTHER | 0 | Not reported | 01/01/2014 | 01/03/2014 |
| CAMPBELL BARBARA E | OTHER | 0 | Not reported | 03/01/2013 | 03/01/2013 |
| BANK OF AMERICA CORP /DE/ | SELL | -100 | $12.77 | 10/18/2011 | 10/25/2011 |
| MACINTOSH ROBERT B | OTHER | 0 | Not reported | 02/19/2010 | 02/24/2010 |
| UBS AG | OPTION | 0 | Not reported | 01/31/2009 | 02/10/2009 |